Brought to you by 
BenevolentAI closes $115mm early equity round
22 Apr 2022
Executive Summary
In what appears to be a Series B round, BenevolentAI (digital healthcare platform that uses artificial intelligence (AI) for drug discovery and development) raised $115mm (at a pre-money valuation of $2bn) from new investors as well as existing backers, including Woodford Investment Management. Credit Suisse was the placement agent.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BenevolentAI closes $115mm early equity round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice